Pfizer (PFE) said Friday that results from a phase-3 study evaluating Hympavzi in adults and adolescents with hemophilia A or B with inhibitors showed a 93% reduction in bleeding compared with on-demand treatment with bypassing agents.

The company said that the mean treated annualized bleeding rate was 1.39 in patients who were dosed with Hympavzi, compared with 19.78 in those given the on-demand treatment.

The results were consistent across hemophilia type, age, and geographies, Pfizer said.

Pfizer said that Hympavzi was administered with a straightforward, once-weekly subcutaneous injection.

Pfizer said it has submitted the data to the US Food and Drug Administration and the European Medicines Agency for review.